Latest filings (excl ownership)
15-12B
Securities registration termination
22 Nov 19
EFFECT
Notice of effectiveness
19 Nov 19
25-NSE
Exchange delisting
12 Nov 19
POS AM
Prospectus update (post-effective amendment)
12 Nov 19
S-8 POS
Registration of securities for employees (post-effective amendment)
12 Nov 19
S-8 POS
Registration of securities for employees (post-effective amendment)
12 Nov 19
SC 14D9/A
Tender offer solicitation (amended)
12 Nov 19
8-K
Termination of a Material Definitive Agreement
12 Nov 19
SC TO-T/A
Third party tender offer statement (amended)
12 Nov 19
10-Q
2019 Q3
Quarterly report
12 Nov 19
SC TO-T/A
Third party tender offer statement (amended)
1 Nov 19
SC 14D9/A
Tender offer solicitation (amended)
1 Nov 19
SC 14D9
Tender offer solicitation
11 Oct 19
SC TO-T
Third party tender offer statement
11 Oct 19
SC14D9C
Written communication relating to third party tender offer
3 Oct 19
8-K
Entry into a Material Definitive Agreement
3 Oct 19
SC TO-C
Information about tender offer
1 Oct 19
SC TO-C
Information about tender offer
1 Oct 19
SC14D9C
Written communication relating to third party tender offer
30 Sep 19
8-K
Other Events
30 Sep 19
10-Q
2019 Q2
Quarterly report
6 Aug 19
8-K
Dova Pharmaceuticals Reports Second Quarter 2019
6 Aug 19
8-K
Company Strengthens Thrombocytopenia Portfolio with ITP Approval and Expanded Partnership with Salix for Chronic Liver Disease (CLD) Indication
27 Jun 19
10-Q
2019 Q1
Quarterly report
7 May 19
8-K
Dova Pharmaceuticals Reports First Quarter 2019 Operating and Financial Results
7 May 19
8-K
Submission of Matters to a Vote of Security Holders
26 Apr 19
DEFA14A
Additional proxy soliciting materials
15 Mar 19
DEF 14A
Definitive proxy
15 Mar 19
10-K
2018 FY
Annual report
5 Mar 19
8-K
Dova Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Operating and Financial Results
5 Mar 19
8-K
Departure of Directors or Certain Officers
8 Feb 19
8-K
Regulation FD Disclosure
7 Jan 19
8-K
Dova Pharmaceuticals Announces Management Changes
20 Dec 18
CT ORDER
Confidential treatment order
14 Dec 18
10-Q
2018 Q3
Quarterly report
8 Nov 18
8-K
Dova Pharmaceuticals Reports Third Quarter 2018 Operating and Financial Results
8 Nov 18
8-K
Entry into a Material Definitive Agreement
4 Oct 18
8-K
Regulation FD Disclosure
2 Oct 18
8-K
Entry into a Material Definitive Agreement
27 Sep 18
CT ORDER
Confidential treatment order
7 Sep 18
Latest ownership filings
SC 13G/A
Dova Pharmaceuticals Inc.
18 Nov 19
4
JOSEPH EDELMAN
15 Nov 19
4
DAVID ZACCARDELLI
12 Nov 19
4
Nancy Wysenski
12 Nov 19
4
Sean Stalfort
12 Nov 19
4
Alfred J Novak
12 Nov 19
4
Paul B Manning
12 Nov 19
4
Kevin Laliberte
12 Nov 19
4
ROGER JEFFS
12 Nov 19
4
Jason Hoitt
12 Nov 19
4
Mark W Hahn
12 Nov 19
4
Steven M. Goldman
12 Nov 19
4
LEE F MD PhD ALLEN
12 Nov 19
4
DAVID ZACCARDELLI
2 Oct 19
4
LEE F MD PhD ALLEN
2 Oct 19
4
Mark W Hahn
2 Oct 19
4
Jason Hoitt
2 Oct 19
4
Kevin Laliberte
2 Oct 19
4
Kevin Laliberte
27 Sep 19
4
Paul B Manning
12 Aug 19
4
Kevin Laliberte
1 Aug 19
4
LEE F MD PhD ALLEN
1 Aug 19
4
Jason Hoitt
16 Jul 19
4
JOSEPH EDELMAN
11 Jul 19
4
JOSEPH EDELMAN
9 Jul 19
4
JOSEPH EDELMAN
3 Jul 19
4
DAVID ZACCARDELLI
3 Jul 19
4
Mark W Hahn
2 Jul 19
4
ROGER JEFFS
2 Jul 19
4
Kevin Laliberte
2 Jul 19
4
LEE F MD PhD ALLEN
2 Jul 19
4
Jason Hoitt
2 Jul 19
4
JOSEPH EDELMAN
1 Jul 19
4
Steven M. Goldman
27 Jun 19
4
Steven M. Goldman
24 Jun 19
4
Steven M. Goldman
3 Jun 19
4
Steven M. Goldman
30 Apr 19
4
ROGER JEFFS
30 Apr 19
4
Alfred J Novak
30 Apr 19
4
Nancy Wysenski
30 Apr 19